Expert Review of Anticancer Therapy

Papers
(The H4-Index of Expert Review of Anticancer Therapy is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-07-01 to 2025-07-01.)
ArticleCitations
The RACE for children act at one year: progress in pediatric development of molecularly targeted oncology drugs80
Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review70
Prognostic impact of renin-angiotensin system inhibitors in patients with ovarian cancer: a meta-analysis of real-world evidence39
An evaluation of nivolumab plus gemcitabine and cisplatin in the treatment of advanced urothelial carcinoma38
PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects28
Clinical characteristics and outcomes among patients with subcutaneous panniculitis-like T-cell lymphoma28
Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope?26
Prevailing challenges in personalized treatment for metastatic renal cell carcinoma: a narrative review25
Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia25
Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma23
Progress in the development of tissue-based biomarkers for urothelial cancer23
2021 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma22
Efficacy and toxicity of drugs targeting KRAS G12C mutation in non-small cell lung cancer: a meta-analysis21
Current status and novel insights into the role of metastasectomy in the era of immunotherapy20
The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan19
Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer19
Progress in histology specific treatments in soft tissue sarcoma19
Current management of familial adenomatous polyposis18
0.069375991821289